Search Results - "Verwey, N. A."

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease by VAN DER VLIES, A. E, VERWEY, N. A, BOUWMAN, F. H, BLANKENSTEIN, M. A, KLEIN, M, SCHELTENS, P, VAN DER FLIER, W. M

“…To investigate the relationship between CSF biomarkers and cognitive profiles in Alzheimer disease (AD). We included 177 patients with AD. Digit Span, Visual…”
Get full text

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort by Schoonenboom, N S M, Reesink, F E, Verwey, N A, Kester, M I, Teunissen, C E, van de Ven, P M, Pijnenburg, Y A L, Blankenstein, M A, Rozemuller, A J, Scheltens, P, van der Flier, W M

“…To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types…”
Get full text

Assessment of cognition in Parkinson's disease by MARINUS, J, VISSER, M, VERWEY, N. A, VERHEY, F. R. J, MIDDELKOOP, H. A. M, STIGGELBOUT, A. M, VAN HILTEN, J. J

“…To develop a short, practical instrument that is sensitive to the specific cognitive deficits in Parkinson's disease (PD) for comparing groups in research…”
Get full text

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease by HENNEMAN, W. J. P, VRENKEN, H, VAN DER FLIER, W. M, BARNES, J, SLUIMER, I. C, VERWEY, N. A, BLANKENSTEIN, M. A, KLEIN, M, FOX, N. C, SCHELTENS, P, BARKHOF, F

“…To investigate whether baseline CSF biomarkers are associated with hippocampal atrophy rate as a measure of disease progression in patients with Alzheimer…”
Get full text

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease by Verwey, N A, van der Flier, W M, Blennow, K, Clark, C, Sokolow, S, De Deyn, P P, Galasko, D, Hampel, H, Hartmann, T, Kapaki, E, Lannfelt, L, Mehta, P D, Parnetti, L, Petzold, A, Pirttila, T, Saleh, L, Skinningsrud, A, Swieten, J C V, Verbeek, M M, Wiltfang, J, Younkin, S, Scheltens, P, Blankenstein, M A

“…Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but…”
Get more information

New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population by Bouwman, F H, Verwey, N A, Klein, M, Kok, A, Blankenstein, M A, Sluimer, J D, Barkhof, F, van der Flier, W M, Scheltens, P

“…In the newly proposed research criteria for Alzheimer's disease (AD), patients are defined as having memory dysfunction in addition to either hippocampal…”
Get more information

Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration by Petzold, A., Verwey, N.A., van Uffelen, K., Blankenstein, M.A., Teunissen, C.

“…[Display omitted] ▶ A high analytical accuracy is needed to establish cerebrospinal fluid biomarkers as additional diagnostic criteria in neurological…”
Get full text

Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology by Boertien, Jeffrey M., van der Zee, Sygrid, Chrysou, Asterios, Gerritsen, Marleen J. J., Jansonius, Nomdo M., Spikman, Jacoba M., van Laar, Teus, Verwey, N. A., Van Harten, B., Portman, A. T., Langedijk, M. J. H., Oomes, P. G., Jansen, B. J. A. M., Van Wieren, T., Van den Bogaard, S. J. A., Van Steenbergen, W., Duyff, R., Van Amerongen, J. P., Fransen, P. S. S., Polman, S. K. L., Zwartbol, R. T., Van Kesteren, M. E., Braakhekke, J. P., Trip, J., Koops, L., De Langen, C. J., De Jong, G., Hartono, J. E. S., Ybema, H., Bartels, A. L., Reesink, F. E., Postma, A. G., Vonk, G. J. H., Oen, J. M. T. H., Brinkman, M. J., Mondria, T., Holscher, R. S., Van der Meulen, A. A. E., Rutgers, A. W. F., Boekestein, W. A., Teune, L. K., Orsel, P. J. L., Hoogendijk, J. E., Van Laar, T.

“…Abstract Background Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and…”
Get full text

Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease by Boertien, Jeffrey M., Murtomäki, Kirsi, Pereira, Pedro A. B., van der Zee, Sygrid, Mertsalmi, Tuomas H., Levo, Reeta, Nojonen, Tanja, Mäkinen, Elina, Jaakkola, Elina, Laine, Pia, Paulin, Lars, Pekkonen, Eero, Kaasinen, Valtteri, Auvinen, Petri, Scheperjans, Filip, van Laar, Teus

“…Gut microbiota alterations in Parkinson’s disease (PD) have been found in several studies and are suggested to contribute to the pathogenesis of PD. However,…”
Get full text

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort by SCHOONENBOOM, N. S. M, REESINK, F. E, VAN DER FLIER, W. M, VERWEY, N. A, KESTER, M. I, TEUNISSEN, C. E, VAN DE VEN, P. M, PIJNENBURG, Y. A. L, BLANKENSTEIN, M. A, ROZEMULLER, A. J, SCHELTENS, P

Get full text

An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels by Petzold, A., Chapman, M.D., Schraen, S., Verwey, N.A., Pasquier, F., Bombois, S., Brettschneider, J., Fox, N.C., von Arnim, C.A.F., Teunissen, C., Pijnenburg, Y., Riepe, M.W., Otto, M., Tumani, H., Scheltens, P., Buee, L., Rossor, M.N.

“…Newly proposed diagnostic criteria for Alzheimer's disease include cerebrospinal fluid (CSF) tau levels as one core supportive criterion. The published high…”
Get full text

Impaired facial emotion recognition in relation to social behaviours in de novo Parkinson's disease by Slomp, Anne Carien, Zee, Sygrid, Boertien, Jeffrey M., Gerritsen, Marleen J. J., Laar, Teus, Spikman, Jacoba M., Verwey, N. A., Van Harten, B., Portman, A. T., Langedijk, M. J. H., Oomes, P. G., Jansen, B. J. A. M., Van Wieren, T., Van den Bogaard, S. J. A., Van Steenbergen, W., Duyff, R., Van Amerongen, J. P., Fransen, P. S. S., Polman, S. K. L., Zwartbol, R. T., Van Kesteren, M. E., Braakhekke, J. P., Trip, J., Koops, L., De Langen, C. J., De Jong, G., Hartono, J. E. S., Ybema, H., Bartels, A. L., Reesink, F. E., Postma, A. G., Vonk, G. J. H., Oen, J. M. T. H., Brinkman, M. J., Mondria, T., Holscher, R. S., Van der Meulen, A. A. E., Rutgers, A. W. F., Boekestein, W. A., Teune, L. K., Orsel, P. J. L., Hoogendijk, J. E., Van Laar, T.

“…Facial emotion recognition (FER) is a crucial component of social cognition and is essential in social‐interpersonal behaviour regulation. Although FER…”
Get full text

An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels : Beta-amylid and tau protein abnormalities in Alzheimer's disease by PETZOLD, A, CHAPMAN, M. D, PIJNENBURG, Y, RIEPE, M. W, OTTO, M, TUMANI, H, SCHELTENS, P, BUEE, L, ROSSOR, M. N, SCHRAEN, S, VERWEY, N. A, PASQUIER, F, BOMBOIS, S, BRETTSCHNEIDER, J, FOX, N. C, VONARNIM, C. A. F, TEUNISSEN, C

Get full text

Quantification of amyloid-beta 40 in cerebrospinal fluid by Verwey, Nicolaas A., Veerhuis, Robert, Twaalfhoven, Harry A.M., Wouters, Dorine, Hoozemans, Jeroen J.M., Bollen, Yves J.M., Killestein, Joep, Bibl, Mirko, Wiltfang, Jens, Hack, C. Erik, Scheltens, Philip, Blankenstein, Marinus A.

“…Truncated forms and full-length forms of the amyloid-beta 40 (Aβ40) are key molecules in the pathogenesis of dementia, and are detectable in CSF. Reliable…”
Get full text

An unbiased, staged, multicentre, validation strategy for Alzheimer' s disease CSF tau levels by Petzold, A, Chapman, MD, Schraen, S, Verwey, NA, Pasquier, F, Bombois, S, Brettschneider, J, Fox, N C, Von Arnim, CAF, Teunissen, C, Pijnenburg, Y, Riepe, M W, Otto, M, Tumani, H, Scheltens, P, Buee, L, Rossor, M N

“…Newly proposed diagnostic criteria for Alzheimer's disease include cerebrospinal fluid (CSF) tau levels as one core supportive criterion. The published high…”
Get full text

Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease by Verwey, Nicolaas A, Schuitemaker, Alie, van der Flier, Wiesje M, Mulder, Sandra D, Mulder, Cees, Hack, C Erik, Scheltens, Philip, Blankenstein, Marinus A, Veerhuis, Robert

“…Serum amyloid P component (SAP), present in amyloid-beta (Abeta) plaques in Alzheimer's disease (AD), may protect Abeta deposits against proteolysis, thereby…”
Get more information

Borobudur: Mysteriegebeuren in steen, Verval en restauratie, Oudjavaans volksleven by VERWEY, A. H. N.

Get full text

A.J.BERNET KEMPERS, Borobudur: Mysteriegebeuren in steen, Verval en restauratie, Oudjavaans volksleven (Book Review) by Verwey, A H N

Get full text